GlassScriptPhysician profile
Ashkan J Ghorbani
NPI 1851392039
$27,018.93
in general payments reported to CMS, 2019-2025
43 companies · $4,876 in 2025
The $4,876 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,285 · 2020: $1,790 · 2021: $2,900 · 2022: $4,238 · 2023: $5,595 · 2024: $5,334 · 2025: $4,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,633.11 |
| Education | $172.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,493.26 | 2019-2025 | |
| Janssen Biotech, INC. | $2,905.28 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $2,319.98 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $2,258.57 | 2019-2025 | |
| Incyte Corporation | $1,703.93 | 2021-2025 | Opzelura |
| Amgen INC. | $1,632.62 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $1,611.08 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $1,423.85 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Arcutis Biotherapeutics, INC. | $1,307.50 | 2023-2025 | Zoryve |
| Genzyme Corporation | $1,235.14 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,101.59 | 2019-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $698.22 | 2019-2025 | Siliq, Targretin, Duobrii |
| Pfizer INC. | $655.27 | 2019-2025 | |
| Dermavant Sciences, INC. | $555.92 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $543.68 | 2022-2025 | Sotyktu |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashkan Ghorbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.